Myriad Genetics announced that James Evans will retire as its CFO "in order to attend to family health issues." Evans will continue to perform his duties until a replacement is found. Myriad said it will hire an executive search firm to identify candidates for consideration.
Evans joined Myriad in 1995 as corporate controller and was promoted to VP of finance in July 2005. He became CFO in November 2007. Evans played a leading role in Myriad's recent acquisitions of Rules-Based Medicine and Crescendo Biosciences.